Making Hay Monday – May 19th, 2025
Making Hay Monday
On when/if to sell down
Reid, Deutsche Bank
One of this newsletter’s most repeated themes has been what we’ve often called America’s 4F condition: its Federal Fiscal Funding Fiasco. The reality is the U.S. continues to run deficits that should only be seen during hot wars and cold economies (bordering on depressions, in the latter case).
Moody’s has belatedly woken up to the gravity of the situation by downgrading America’s sovereign debt to AA1. This is now the third, and last, major credit rating agency that has removed the USA’s once sacrosanct AAA rating. Considering that U.S. Treasury debt is the backbone of the global financial system, this should be exceedingly concerning.
The soothing argument is that S&P lowered America’s credit rating to AA+ in 2011 and, since then, its world famous index, the S&P 500, has soared by 450%. However, over the past 14 years, the U.S. government’s debt-to-GDP has vaulted from 40% to 100%, based on publicly held federal IOUs, per the above chart on the right. More worrisome is that total debt outstanding is now around 130%. This includes, for example, government debt held by the Social Security Trust Fund, and it is even higher than at the end of WWII.
To make matters worse, not that they need to be, Moody’s is predicting the USA’s debt-to-GDP will spike another 35% by 2035. Similarly, annual deficits will rise from an already inexcusable 7% of GDP to 9% by then. It’s hard to see how such fiscal recklessness will not lead to a funding crisis for America long before a decade passes.
Wood, Jefferies
Markets have been rejoicing that tariffs will not be as punitive as feared early last month. However, they are likely to remain near the highest of the last 100 years.
While most countries will be subject to “only” a 10% levy, much higher tariffs on China, from whom the U.S. continues to import nearly $500 billion of goods annually, second only to Mexico, elevates the average. Yale University’s Budget Lab estimates this will cost the average American household an extra $2800/year.
“To everything there is a season, and a time to every purpose under heaven: A time to be born, and a time to die; a time to plant, and a time to pluck up that which is planted.”
The Book of Ecclesiastes, covered by The Byrds approximately 2500 years later.
Harvest Time
Shutterstock
Before I delve into this week’s potential Pick to Click (emphasis on potential) I would like to suggest a bit of profit-plucking on ideas previously highlighted in this newsletter. In my view, far too much attention is devoted to buy stories and not nearly enough to when to harvest gains. Most of the successful investors I know and/or track closely admit that selling is the hardest part.
One quick, but related, side road on that score is a stock which was the recipient of intense media attention last week, though, unfortunately, of the unwanted kind. United Healthcare (UNH) has been one of the most spectacular large-cap winners of the last 15 years. It had rocketed from $34 in 2010 to $630 at its peak in late 2024. In fact, as recently as April 11th, it was trading at $600.
Since then, it has seen one of the most rapid and precipitous declines a mega-cap stock has ever endured. It now trades at $315, after hitting $249 last week, representing a loss of almost $300 billion. As CNBC’s Brian Sullivan observed last Thursday, UNH has lost the equivalent of a Bank of America. He went on to say that he doesn’t believe another Dow component has experienced that type of market-value evisceration in just a month. My belief is that he is correct.
UNH has also been an interesting case study in both breakouts and breakdowns. On the former, it had its upside range expansion last July when it broke above $550 on its way to $630 four months later. That was certainly a nice return in a short time, but to capitalize on it one would have needed to sell into the rally which, admittedly, wasn’t a corker. More critically, on the point of the importance of selling, in this case on the way down, it took out multi-year support at $440 late last month.
Five-year Price Chart of United Healthcare
Shutterstock
Rapidly reacting to that downside range expansion would have saved some serious coin. This is a pattern that has repeated continually over the years. It’s particularly critical, in my view, with financial stocks, which can immolate almost overnight. (See the three large bank failures in early 2023, per the below.)
At this point, UNH may be a great buy, but there is a potential criminal investigation hanging over its head. Usually, with these types of situations, it’s best to wait until there is some extensive base-building and strong evidence of a broken downtrend. Fleeting snap-back rallies are certainly possible, even likely, but those are tricky to play. (Actually, since I first composed these words, one has indeed occurred.)
Fortunately, this newsletter avoided highlighting UNH, despite its breakout last summer. Chalk that up to dumb luck. However, relevant to the theme of this Making Hay Monday (MHM), there were a few stocks we brought to your attention that now strike me as definitely in the sell-down, maybe even sell-out, zone…
Subscribe to Haymaker to unlock the rest.
Become a paying subscriber of Haymaker to get access to this post and other subscriber-only content.
A subscription gets you:
 | Subscriber-only posts and full archive |
| Post comments and join the community |
IMPORTANT DISCLOSURES
This material has been distributed solely for informational and educational purposes only and is not a solicitation or an offer to buy any security or to participate in any trading strategy. All material presented is compiled from sources believed to be reliable, but accuracy, adequacy, or completeness cannot be guaranteed, and David Hay makes no representation as to its accuracy, adequacy, or completeness.
The information herein is based on David Hay’s beliefs, as well as certain assumptions regarding future events based on information available to David Hay on a formal and informal basis as of the date of this publication. The material may include projections or other forward-looking statements regarding future events, targets or expectations. Past performance is no guarantee of future results. There is no guarantee that any opinions, forecasts, projections, risk assumptions, or commentary discussed herein will be realized or that an investment strategy will be successful. Actual experience may not reflect all of these opinions, forecasts, projections, risk assumptions, or commentary.
David Hay shall have no responsibility for: (i) determining that any opinion, forecast, projection, risk assumption, or commentary discussed herein is suitable for any particular reader; (ii) monitoring whether any opinion, forecast, projection, risk assumption, or commentary discussed herein continues to be suitable for any reader; or (iii) tailoring any opinion, forecast, projection, risk assumption, or commentary discussed herein to any particular reader’s investment objectives, guidelines, or restrictions. Receipt of this material does not, by itself, imply that David Hay has an advisory agreement, oral or otherwise, with any reader.
David Hay serves on the Investment Committee in his capacity as Co-Chief Investment Officer of Evergreen Gavekal (“Evergreen”), registered with the Securities and Exchange Commission as an investment adviser under the Investment Advisers Act of 1940. The registration of Evergreen in no way implies a certain level of skill or expertise or that the SEC has endorsed the firm or David Hay. Investment decisions for Evergreen clients are made by the Evergreen Investment Committee. Please note that while David Hay co-manages the investment program on behalf of Evergreen clients, this publication is not affiliated with Evergreen and do not necessarily reflect the views of the Investment Committee. The information herein reflects the personal views of David Hay as a seasoned investor in the financial markets and any recommendations noted may be materially different than the investment strategies that Evergreen manages on behalf of, or recommends to, its clients.
Different types of investments involve varying degrees of risk, and there can be no assurance that the future performance of any specific investment, investment strategy, or product made reference to directly or indirectly in this material, will be profitable, equal any corresponding indicated performance level(s), or be suitable for your portfolio. Due to rapidly changing market conditions and the complexity of investment decisions, supplemental information and other sources may be required to make informed investment decisions based on your individual investment objectives and suitability specifications. All expressions of opinions are subject to change without notice. Investors should seek financial advice regarding the appropriateness of investing in any security or investment strategy discussed in this presentation.
20250520
